DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?

DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and Takedas exit complicate the outlook.

Go to News Site